JP6706020B2 - 視覚障害を処置する組成物と方法 - Google Patents

視覚障害を処置する組成物と方法 Download PDF

Info

Publication number
JP6706020B2
JP6706020B2 JP2017529981A JP2017529981A JP6706020B2 JP 6706020 B2 JP6706020 B2 JP 6706020B2 JP 2017529981 A JP2017529981 A JP 2017529981A JP 2017529981 A JP2017529981 A JP 2017529981A JP 6706020 B2 JP6706020 B2 JP 6706020B2
Authority
JP
Japan
Prior art keywords
crystallin
lanosterol
cataracts
cataract
lens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017529981A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017525769A5 (enExample
JP2017525769A (ja
Inventor
チャン，カン
ホウ，ルイ
カイ，フイミン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
University of California Berkeley
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2017525769A publication Critical patent/JP2017525769A/ja
Publication of JP2017525769A5 publication Critical patent/JP2017525769A5/ja
Application granted granted Critical
Publication of JP6706020B2 publication Critical patent/JP6706020B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
JP2017529981A 2014-08-22 2015-08-24 視覚障害を処置する組成物と方法 Active JP6706020B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462040721P 2014-08-22 2014-08-22
US62/040,721 2014-08-22
US201562194120P 2015-07-17 2015-07-17
US62/194,120 2015-07-17
PCT/US2015/046453 WO2016029199A1 (en) 2014-08-22 2015-08-24 Compositions and methods to treat vision disorders

Publications (3)

Publication Number Publication Date
JP2017525769A JP2017525769A (ja) 2017-09-07
JP2017525769A5 JP2017525769A5 (enExample) 2018-10-11
JP6706020B2 true JP6706020B2 (ja) 2020-06-03

Family

ID=55351326

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017529981A Active JP6706020B2 (ja) 2014-08-22 2015-08-24 視覚障害を処置する組成物と方法

Country Status (13)

Country Link
US (1) US10471076B2 (enExample)
EP (1) EP3182977B1 (enExample)
JP (1) JP6706020B2 (enExample)
KR (1) KR20170048426A (enExample)
CN (2) CN111529481B (enExample)
AU (1) AU2015305199A1 (enExample)
BR (1) BR112017003529A2 (enExample)
CA (1) CA2958868A1 (enExample)
EA (1) EA035798B1 (enExample)
HK (1) HK1243325A1 (enExample)
MX (1) MX2017002374A (enExample)
SG (1) SG11201701377YA (enExample)
WO (1) WO2016029199A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017003529A2 (pt) 2014-08-22 2019-08-20 Guangzhou Kangrui Biological Pharmaceutical Tech Co Ltd composições e métodos para tratar distúrbios visuais.
EP3328389A1 (en) * 2015-07-27 2018-06-06 Catacore, Inc. Compositions for the treatment of cataracts
CN109481450B (zh) * 2015-09-02 2021-07-23 盛世泰科生物医药技术(苏州)有限公司 一种用于预防和治疗白内障的眼用制剂及其制备方法
CN107397745A (zh) * 2016-08-24 2017-11-28 上海毕傲图生物科技有限公司 唑类化合物眼用制剂
CN106344587A (zh) * 2016-08-24 2017-01-25 上海毕傲图生物科技有限公司 羊毛甾醇类化合物眼用制剂
JP6704535B2 (ja) * 2017-01-25 2020-06-03 中山大学中山眼科中心 ラノステロールプロドラッグ化合物、その製造方法及び応用
WO2019097434A1 (en) * 2017-11-17 2019-05-23 Mahmood Piraee Combinations of lanosterol or 25-hydroxycholesterol including derivatives thereof useful in the treatment of lens disorders
CN109985052A (zh) * 2017-12-29 2019-07-09 上海蓝木化工有限公司 三萜类化合物的新用途
MX2020010502A (es) * 2018-04-05 2021-03-25 Calasia Pharmaceuticals Inc Agentes farmacológicos para el tratamiento de enfermedades oculares.
WO2020020306A1 (zh) * 2018-07-25 2020-01-30 中山大学中山眼科中心 一种羊毛甾醇前药化合物的晶型及其应用
US12329763B2 (en) * 2019-03-04 2025-06-17 Guangzhou Ocusun Ophthalmic Biotechnology Co., Ltd. Composition of lanosterol prodrug compound, preparation method therefor and use thereof
MX2021009520A (es) 2021-08-06 2023-02-07 Foodvica S A De C V Composicion oftalmica para el tratamiento de trastornos visuales.
CN115737654B (zh) * 2021-09-03 2025-11-21 成都瑞沐生物医药科技有限公司 一种滴眼给药预防和/或治疗白内障的眼用制剂
CN114796451B (zh) * 2022-02-09 2023-06-06 上海瑞吉康生物医药有限公司 使用多肽治疗白内障的方法
WO2023198192A1 (zh) * 2022-04-15 2023-10-19 广州润尔眼科生物科技有限公司 甾体化合物在制备预防和/或治疗老花眼的药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9216106B2 (en) * 2003-04-09 2015-12-22 Directcontact Llc Device and method for the delivery of drugs for the treatment of posterior segment disease
WO2005084208A2 (en) * 2004-02-27 2005-09-15 New York University A novel class of sterol ligands and their uses in regulation of cholesterol and gene expression
US7517870B2 (en) * 2004-12-03 2009-04-14 Fondazione Telethon Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization
US20100068251A1 (en) * 2006-10-10 2010-03-18 Jina Pharmaceuticals, Inc. Aqueous Systems For The Preparation Of Lipid Based Pharmaceutical Compounds; Compositions, Methods, And Uses Thereof
EP2255788B1 (en) * 2008-02-29 2015-07-22 Nagoya Industrial Science Research Institute Liposome for delivery to posterior segment of eye and pharmaceutical composition for disease in posterior segment of eye
MX2011001411A (es) * 2008-08-05 2011-03-15 Amazonia Fitomedicamentos Ltda Usos farmaceuticos de lanosta-8,24-dien-3-ols.
SG11201500288QA (en) * 2012-07-17 2015-02-27 Univ Michigan Inhibitors of alpha-crystallin aggregation for the treatment for cataract
KR20150046300A (ko) * 2012-08-31 2015-04-29 보오슈 앤드 롬 인코포레이팃드 오메가-3 지방산을 함유하는 안과용 조성물
BR112017003529A2 (pt) 2014-08-22 2019-08-20 Guangzhou Kangrui Biological Pharmaceutical Tech Co Ltd composições e métodos para tratar distúrbios visuais.

Also Published As

Publication number Publication date
CN107206009A (zh) 2017-09-26
SG11201701377YA (en) 2017-03-30
WO2016029199A1 (en) 2016-02-25
EP3182977A4 (en) 2018-04-11
EA035798B1 (ru) 2020-08-12
EA201790397A1 (ru) 2017-08-31
CA2958868A1 (en) 2016-02-25
US10471076B2 (en) 2019-11-12
JP2017525769A (ja) 2017-09-07
US20170065617A1 (en) 2017-03-09
BR112017003529A2 (pt) 2019-08-20
HK1243325A1 (zh) 2018-07-13
CN111529481B (zh) 2023-09-15
MX2017002374A (es) 2017-09-15
KR20170048426A (ko) 2017-05-08
EP3182977A1 (en) 2017-06-28
CN111529481A (zh) 2020-08-14
AU2015305199A1 (en) 2017-04-13
EP3182977B1 (en) 2021-05-05
CN107206009B (zh) 2020-03-27

Similar Documents

Publication Publication Date Title
JP6706020B2 (ja) 視覚障害を処置する組成物と方法
US20190117675A1 (en) Compositions And Methods To Treat And/Or Prevent Vision Disorders Of The Lens Of The Eye
Zhao et al. Lanosterol reverses protein aggregation in cataracts
US9675623B2 (en) Non-surgical method of treatment for cataract
JP2018035197A (ja) Ａｐｐ特異性のｂａｃｅ（ａｓｂｉ）およびその使用
US20170173029A1 (en) 3-(4-((4-(morpholinomethyl-benzyl)oxy)-1 -oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus
Liang et al. miR-328-3p affects axial length via multiple routes and anti-miR-328-3p possesses a potential to control myopia progression
US20200140500A1 (en) High throughput methods, protein inhibitors, and uses thereof
US20240207244A1 (en) Compositions and methods for treating neurodegenerative disorders through inhibition of cd44 and ferm protein interaction
CN117177742A (zh) 溶酶体相关膜蛋白靶向化合物及其用途
US20200138832A1 (en) Compounds and prodrugs thereof for the treatment of ophthalmic disease
HK40011572A (en) Non-surgical method of treatment for cataract
HK1212271B (zh) 治疗白内障的非手术方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180820

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180820

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190416

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190513

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190730

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191108

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200415

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200512

R150 Certificate of patent or registration of utility model

Ref document number: 6706020

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250